PNPLA3 and metabolic dysfunction-associated steatotic liver disease: In these studies, the “G” allele of PNPLA3 has been implicated as a potential drug target for alcohol-related cirrhosis, Non-Alcoholic Fatty Liver Disease (NAFLD) and hepatic steatosis.